Carney complex (CC), Peutz-Jeghers syndrome (PJS), Cowden disease (CD), and Bannayan-Zonana syndrome (BZS) share clinical features, such as mucocutaneous lentigines and multiple tumors (thyroid, breast, ovarian, and testicular neoplasms), and autosomal dominant inheritance. A genetic locus has been identified for CC on chromosome 2 (2p16), and the genes for PJS, CD, and BZS were recently identified; genetic heterogeneity appears likely in both CC and PJS. The genes for PJS and CD/BZS, STK11/LKB1 and PTEN, respectively, may act as tumor suppressors, because loss of heterozygosity (LOH) of the PJS and CD/BZS loci has been demonstrated in tumors excised from patients with these disorders. We studied 2 families with CC in whom the disease could not be shown to segregate with polymorphic markers from the 2p16 locus. Their members presented with lesions frequently seen in PJS and the other lentiginosis syndromes. We also tested 16 tumors and cell lines established from patients with CC for LOH involving the PJS and CD/BZS loci. DNA was extracted from peripheral blood, tumor cell lines, and tissues and subjected to PCR amplification with primers from microsatellite sequences flanking the STK11/LKB1 and PTEN genes on 19p13 and 10q23, respectively, and a putative PJS locus on 19q13. All loci were excluded as candidates in both families with LOD scores less than Ϫ2 and/or by haplotype analysis. LOH for these loci was not present in any of the tumors that were histologically identical to those seen in PJS. The overall rate of LOH for the PJS and CD/BZS loci in tumors from patients with CC was less than 10%. We conclude that despite substantial clinical overlap among CC, PJS, CD, and BZS, LOH for the STK11 and PTEN loci is an infrequent event in CC-related tumors. Linkage analysis excluded the PJS and CD/BZS loci on chromosomes 19 (19p13 and 19q13) and 10 (10q23) from harboring the gene defect(s) responsible for the phenotype in these 2 families. (J Clin Endocrinol Metab 83: 2972-2976 
T HE FAMILIAL lentiginoses are syndromes associated with numerous skin lesions and an increased predisposition toward neoplasms, in particular endocrine tumors (1) . The prototype of these conditions is Peutz-Jeghers syndrome (PJS) [Mendelian Inheritance in Man (MIM) 175200] (2), which was described in 1949 (3) . This syndrome is inherited in an autosomal dominant manner and is characterized by skin and mucosal lentigines, gastrointestinal hamartomatous polyps, and breast, thyroid, and testicular tumors (4 -7). Carney complex (CC; MIM 160980) is another familial multiple neoplasia and lentiginosis syndrome associated with lentigines and a variety of nonendocrine and endocrine tumors (8) . These include myxomas of the heart, skin, breast, and other sites (8) , primary pigmented nodular adrenocortical disease (9) , and testicular, thyroid gland, breast and other tumors (9, 10) .
CC and PJS share several features, and their differential diagnosis in individual patients with unusual skin pigmentation and multiple tumors is often difficult. The presence of cardiac and other myxomas may help with the diagnosis, but these tumors may not be present in patients with CC (8) . CC, as PJS and the other familial lentiginoses, is inherited in an autosomal dominant manner (11) . Lentigines in PJS are indistinguishable from those in CC (8) ; their presence, particularly in the mucosae, serves to identify families affected with any of the lentiginoses. Among the nongastrointestinal neoplasms associated with PJS, tumors, including thyroid, ovarian, and testicular Sertoli cell neoplasms, are relatively frequent, and all are common in CC (8, 12, 13) . In both PJS and CC, large cell, often calcifying, Sertoli cell tumors can produce estradiol, which may lead to precocious puberty or gynecomastia (14, 15) . At least one patient with CC and intestinal polyposis and another with a pancreatic tumor have been reported (16) .
Because of their substantial phenotypic similarities, it has been suggested that PJS, the other lentiginoses, and CC may share a common molecular etiology (1) . An example of such clinical and genetic overlap is that of two related familial syndromes associated with skin abnormalities and endocrine tumors: Cowden disease (CD; MIM 158350) (2, 17) and Ruvalcaba-Myhre-Smith or Bannayan-Zonana syndrome (BZS; MIM 153480) (2, 18, 19) . Despite certain differences, these syndromes share hamartomatous polyps, endocrine abnormalities, and mucocutaneous lesions, and both are caused by mutations in the same gene on chromosome 10 that codes for the PTEN protein, a dual specificity phosphatase (20 -22) .
A genetic locus has been identified for CC (16) on chromosome 2 (2p16), and the PJS gene was recently identified (23) (24) (25) . Germline loss of function mutations in the STK11/ LKB1 gene, which encodes a serine-threonine kinase, lead to PJS (24, 25) . However, not all families with PJS map to the STK11/LKB1 locus; a second locus on 19q13 and possibly other loci appear likely (26, 27) . Likewise, genetic heterogeneity has been documented in CC (28, 29) . A large family with CC that does not map to chromosome 2 was reported (28) , and this finding was confirmed in our laboratory for other families (29) .
In the present study, we investigated two families with CC that did not map to the CNC locus on 2p16 (29) ; both presented with clinical manifestations of PJS. We studied 16 tumors and tumor cell lines from patients with CC for LOH of the PJS and the CD/BZS loci and excluded these loci from harboring the candidate genetic defects responsible for CC in these two families.
Subjects and Methods Subjects
The institutional review boards of the NICHD, NIH, and the Mayo Clinic approved the contact of the families and the participation of their members in the NICHD protocol 95-CH-059 on CC and related disorders. Patients with CC were classified as affected according to the criteria established by Stratakis et al. (16) . Blood and tissue samples were collected from patients belonging to previously described families and sporadic cases (16) . Tissue was collected in surgery from seven of these patients and immediately processed to establish cell lines. The clinical profile of the patients, histology of their tumors, and source of DNA for molecular analysis (frozen tissue or tumor cell line) are listed in Tables  1 and 2 . 
DNA preparation and PCR analysis
Twenty milliliters of blood were obtained from each subject in a heparinized syringe and tube. The peripheral blood lymphocytes were separated on a Ficoll gradient and immortalized with Epstein-Barr virus or used for direct DNA extraction, as previously described (16) .
Genetic analysis
PCR analysis of the tumors was performed with sets of primers for the PJS loci-flanking polymorphic markers D19S413, D19S886, and D19S565 located on 19p13 (23) (24) (25) , and D19S926, D19S877, and D19S891 located on 19q13.4 (26) . The D10S579, D10S1735, and D10S541 markers flanking the CD/BZS locus (in a centromere to telomere order) were also used, as previously described (17, 20) . The sequences and genomic order of these primers are available in the genome database on line (http:// gdbwww.gdb.org/ and http://www-genome.wi.mit.edu). For each of the markers, the reverse primer was end labeled with ␥-32 P, as previously described (16, 30) .
Tumor and linkage analysis
The microsatellite alterations seen in the tumors were classified as previously described (30) . Loss of heterozygosity (LOH) was present when only one allele was evident in tumor DNA vs. two alleles in the corresponding bands of blood DNA. Microsatellite length instability was present when multiple bands were seen in the amplified tumor DNA vs. one or two in peripheral blood DNA. Specimens that were not successfully amplified were excluded from the analysis. The results are expressed as a percentage of the total number of informative loci in both tumor and blood samples. Linkage analysis was performed with the LINKAGE (version 5.1) package of computer programs, as previously described (16, 31) .
Results

Clinical description
The clinical findings in family YC01 are described in Table  1 . This family has been reported previously (32) and was included with the CAR01 code in the series studied by Stratakis et al. (16) . The propositus was studied at the NIH (indicated by the arrow, family member II.5, Table 1 ). Although variable, the pigmentation in this family with CC was similar to that in patients with PJS, with the exception of a pigmented lesion, which to date has been described in only one patient with PJS (3) but was present in all members of the YC01 family (Fig. 1) .
Family YC10 was considered to have PJS, until a heart myxoma was found in the propositus (indicated by the arrow, Table 1); his mother was then found to have multiple breast myxoid fibroadenomas. The other affected members of this family have spotty skin pigmentation that is characteristic of both CNC and PJS, but no endocrine or other tumors (including gastrointestinal hamartomas).
Genetic analysis
LOH for each of the 2 investigated polymorphic markers flanking the PJS locus was present in 1 of the 16 tumors and tumor cell lines derived from patients with CC from YC01 and other families (Table 2 and Fig. 2 ). The overall LOH rate for 19p in these samples was 6.3%, which is not different from LOH rates for random loci in the genome in various tumors (Tables 2 and 3 ) (30, 33) . The observed rate is significantly lower than the 37.5% LOH rate for this genetic locus shown by comparative genomic hybridization in PJS families (23), a percentage that was even higher after microscope-guided laser dissection of abnormal cells from histological slides of tumors from patients with PJS. It is noteworthy that we did not observe any LOH for the PJS locus in tumors from patients with the complex that were histologically identical to those seen in patients with PJS. These lesions included a nonmedullary thyroid carcinoma and a follicular adenoma (specimens 9 and 14), and an ovarian tumor and a large-cell calcifying Sertoli cell tumor (specimens 10 and 16; Table 2 ).
Likewise, there was no significant LOH for the other loci tested in CC tumors in this study. It is noteworthy that there was no significant LOH for the PTEN locus on 10q23 (Table  3) . Linkage analysis using markers corresponding to the PJS loci on 19p13 and 19q13 and the CD/BZS region on 10q23 excluded these loci from harboring the susceptibility genes for CC in these families (LOD scores of Ϫ2 or less; Table 3 ). Haplotype inspection (data not shown) showed that affected individuals within families did not share genotypes, confirming linkage results and exclusion in those particular families in which LOD scores were not lower than Ϫ2 (Table 3) .
Discussion
Genetic heterogeneity has now been confirmed for both CC and PJS. Since the identification of the original locus for each of these two syndromes, on chromosomes 2p and 19p, respectively (16, 23) , and the STK11/LKB1 gene for PJS (24, 25) , families with CC and PJS that did not map to their respective genomic locations or mapped elsewhere have been reported (26 -29) . Because PJS, as well as CD and BZS share a variety of clinical manifestations with CC, we tested the hypothesis that some families with CC may map to the genetic loci of these conditions and that LOH for the PJS and CD/BZS loci was involved in the molecular pathology of CC tumors.
Because the STK11/LKB1 and PTEN genes appear to function as tumor suppressor genes (17, 20 -25) , whereas the function of the CC gene is unknown (30) , it is possible that these molecules are members of a family of proteins that regulate the same cellular process. Examples of such clinical and genetic overlap between various familial syndromes sharing defects in a molecular pathway are well known in tumor genetics. They include the Muir-Torre and hereditary, nonpolyposis colorectal cancer syndromes (34) and the multiple endocrine neoplasia type 2 syndromes and Hirschprung disease (35) . However, in this study, the two non2p-linked CC families did not map to the 19p13, 19q13, and 10q23 loci either, and tumors from patients with CC did not show LOH for these loci despite having an overall significant genomic instability, previously documented by our laboratory and others (30, 36) .
These findings suggest that the PJS and the PTEN genes may not play a significant role in the molecular pathogenesis of tumors associated with CC despite the clinical and histological similarities between these disorders. It should be remembered, however, that the PJS locus was identified by screening only DNA of colonic polyps excised from patients with this syndrome. No other tumors associated with PJS were included in the study by Hemminki et al. (23) , and no polyps or other colonic lesions from patients with CC were available to us. It is possible, therefore, that LOH for the PJS genomic region is necessary for oncogenesis in the colon but not in other organs affected by PJS or CC. According to Knudson's hypothesis (37), LOH is necessary for oncogenesis in the presence of a recessive mutant allele, whereas a dominant mutant allele is sufficient for tumorigenesis. If tissuespecific conditions were to determine the dominant or recessive function of the mutant PJS allele, a variable pattern Table 2) shows LOH for the lower allele, but no other abnormalities are seen in the other pairs of samples.
of LOH for the PJS locus would be observed in the tissues studied from patients with the syndrome. A similar example has been observed for menin, the gene responsible for multiple endocrine neoplasm type 1; there is LOH at the menin locus in most tumors associated with the syndrome (i.e. carcinoids, and parathyroid and pituitary adenomas), but not in others (38) . Thus, the possibility exists that the PJS genes play a role in the expression of the CC phenotype in noncolonic tissues, but do not have a tumor suppression function. In summary, despite substantial clinical overlap among CC, PJS, CD, and BZS, in at least 2 families with the complex that did not map to the CNC locus the disease did not segregate with markers from the PJS and CD/BZS loci. LOH for these loci appears to be a rare and most likely random event in tumors from patients with CC.
